These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24613178)

  • 1. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
    Mentzer D
    Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
    Vassal G
    Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G
    Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
    Ruperto N; Vesely R; Saint-Raymond A; Martini A;
    Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paediatric drug development: the impact of evolving regulations.
    Turner MA; Catapano M; Hirschfeld S; Giaquinto C;
    Adv Drug Deliv Rev; 2014 Jun; 73():2-13. PubMed ID: 24556465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Draft EU regulation on paediatric medicines: some improvements but still far from perfect.
    Prescrire Int; 2006 Feb; 15(81):32-3. PubMed ID: 16548115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Rocchi F; Tomasi P
    Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
    Jackson EL; Feldschreiber P; Breckenridge A
    Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.
    Seyberth HW; Demotes-Mainard J; Wrobel P
    Pediatr Nephrol; 2005 Nov; 20(11):1537-40. PubMed ID: 16167134
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory aspects of clinical trials in children.
    Mentzer D
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():203-7; discussion 207-9. PubMed ID: 20799462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usage of unpublished paediatric data.
    Saint-Raymond A; Pelle B; Zaccaria C; Sennwitz M; Branch S
    Arch Dis Child; 2016 Jan; 101(1):81-4. PubMed ID: 26543071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Better medicines for children].
    Brasseur D
    Rev Med Brux; 2006; 27 Spec No():Sp25-8. PubMed ID: 21818889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More medicines for children: impact of the EU paediatric regulation.
    Nordenmalm S; Tomasi P; Pallidis C
    Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.